Evidence map›Paper›PMID 40718793›Full record

ArticleFrontiers in molecular biosciences2025

Targeting USP42 induces DNA damage and inhibits cell growth in prostate cancer.

Yinghao Zhou, Chenchen Chen, Yibo Meng, Jianchao Ge, Shengkui Meng, Xillong Wang, Yaozong Xu, Guowei Shi, Wandong Yu, Xuetao Hu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yinghao Zhou *Department of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Chenchen Chen *Department of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Yibo MengDepartment of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Jianchao GeDepartment of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Shengkui MengDepartment of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Xillong WangDepartment of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Yaozong XuDepartment of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Guowei ShiDepartment of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Wandong YuDepartment of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Xuetao HuDepartment of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Jun ZhangDepartment of Urology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate cancer (PCa) is one of the most common cancers in men worldwide. During its progression, deubiquitination-mediated alterations in biological processes play critical roles in tumor metabolism, stem cell characteristics, immune evasion, DNA damage repair, and chemoresistance. A comprehensive investigation of the deubiquitinases involved in PCa development holds significant clinical value as regards inhibiting tumor growth and overcoming drug resistance. Methods: Clinical databases were analyzed to identify differentially expressed deubiquitinases in PCa. Immunohistochemical analysis of PCa samples was used to evaluate USP42 expression in normal and tumor tissues. The effects of USP42 inhibition on PCa cell proliferation were assessed both Results: Knockdown of USP42 significantly reduced PCa cell growth both

Indexed as

androgen recepterdeubiquitinaseDNA damage responseolaparibprostate cancer

Identifiers

PMID40718793
PMCPMC12289470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.